Thomas Holbro

Oncology · 2003–2004

A researcher in the Science corpus: 3 papers; trusts 4 researchers and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom Thomas Holbro trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. J. Mendelsohn
  2. Joseph Schlessinger
  3. Y. Yarden
  4. R. Nicholson
  5. H. Lane
  6. J. Baselga

Who trusts Thomas Holbro overall

  1. N. Hynes
  2. Basit Yameen
  3. Divyamani Srinivasan
  4. M. Moasser
  5. W. Choi
  6. H. Ohtsu
  7. H. Lane

Papers from Thomas Holbro's perspective

Ordered by how strongly the researchers Thomas Holbro trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  3. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. (Molecules and Cells)
  4. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
  5. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
  6. Epidermal growth factor receptor: mechanisms of activation and signalling. (Experimental Cell Research)
  7. The ErbB signaling network: receptor heterodimerization in development and cancer (EMBO Journal)
  8. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. (Molecules and Cells)
  9. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: Metalloproteinase inhibitors as a new therapy
  10. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. (Clinical Cancer Research)

Their papers